RDAF welcomes new board members in 2018

    4 Jun, 2018

    In May 2018, the General Assembly of the Rare Disease Action Forum (RDAF) elected the Forum’s board, welcoming two new board members: Ms. Rea Lal, Rare Disease Lead at Pfizer in Switzerland, and Dr. Jacqueline de Sá, General Secretary of the Swiss umbrella patient organization ProRaris. Rea Lal succeeds Dr. Roland Rutschmann, CEO at Curatis who did not run for reelection. The secretariat would like to thank Dr. Roland Rutschmann for the considerable expertise and great contributions he made as a board member since the founding of the RDAF. The new board composition reaffirms the multistakeholder approach of the Forum. The RDAF is looking forward to continuing its efforts to facilitate the development of sustainable solutions that improve the situation of patients with rare diseases in Switzerland.

    Continue reading

    Joint statement on the KVV/OAMal and KLV/OPAS revision

    The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...